Coronavirus (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID- 19 affected people clinically present with symptoms of fever, fatigue, loss of appetite, cough with sputum production, anosmia, nausea, vomiting, gastroenteritis, and shortness of breath. During covid pandemic, to assess the severity, we developed a novel scoring system, i.e., ACHE. The increasing score suggests an increase in severity and a possible increased mortality rate. Different parameters were included in developing a scoring system to evaluate the patient's severity. A Prospective observational study on the Covid-19 mortality risk assessment with a novel evaluation scoring in a tertiary care hospital in Andhra Pradesh. The objective is to predict the mortality risk of COVID-19 patients at admission by a novel scoring system, i.e., ACHE score (Acute covid health evaluation), and to categorize the patient using a novel acute covid health evaluation (ACHE) score—a hospital-based prospective observational study which included 800 cases of covid 19 confirmed by RT – PCR. ACHE was calculated in all these patients based on 4 major parameters: NL neutrophil-lymphocyte ratio (NLR) ratio, CRP(C-REACTVE PROTEIN), D – Dimer &Age group. Different parameters were included in developing the scoring system to evaluate the patient's severity. The novel scoring system ACHE scores>15 had the highest mortality rate. And Majority of the patients out of 800 were in the age group 51-60 (n=208, 26%) and had shown more prevalence, followed by the age group 61-70 (n=178, 22.25%). Among 800 patients, 87 died due to viral pneumonia with cytokine storm, coagulopathy, sepsis, and MODS. In the background of covid pandemic, a simplified way of assessing the severity of covid patients is the need of the hour. ACHE scoring system helped assess the patient's condition and prognosis, thus aiding in making a dynamic decision in managing the patients without any undue delay to reduce morbidity and mortality.

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7, PMID 32007143.
2. Hui DS, I Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020; 91:264-6. doi: 10.1016/j.ijid.2020.01.009, PMID 31953166.
3. Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020;323(15):1499-500. doi: 10.1001/jama.2020.3633, PMID 32159735.
4. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-8. doi: 10.1515/calm-2020-0369, PMID 32286245.
5. Tjendra Y, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C et al. Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020 Dec 1;144(12):1465-74. doi: 10.5858/arpa.2020-0471-SA, PMID 32818235.
6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi: 10.1001/jama.2020.1585, PMID 32031570.
7. Zhang C, Qin L, Li K, Wang Q, Zhao Y, Xu B et al. A novel scoring system for predicting disease severity in COVID-19. Front Cell Infect Microbiol. 2020;10:318. doi: 10.3389/fcimb.2020.00318, PMID 32582575.
8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3, PMID 32171076.
9. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020 Jul;81(1):e6-e12. doi: 10.1016/j.jinf.2020.04.002. PMID 32283162, PMCID PMC7195072.
10. Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. C-reactive protein level may predict the risk of COVID?19 aggravation. Open Forum Infect Dis. 2020;7(5):ofaa153. doi: 10.1093/ofid/ofaa153. (PMC Free article). PMID 32455147 [CrossRef]. Google Scholar.
11. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors, and role in inflammation. Clin Immunol. 2005;117(2):104-11. doi: 10.1016/j.clim.2005.08.004, PMID 16214080CrossRefGoogle Scholar.
12. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case-control study. J Intensive Care. 2020;8:49. doi: 10.1186/s40560-020-00466-z, PMID 32665858.
13. Guan WJ, Ni ZY, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032.
14. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. doi: 10.1111/jth.14768, PMID 32073213.
15. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762-8. doi: 10.1093/cid/ciaa248, PMID 32161940, PMCID PMC7108125.
16. Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of the Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection: A cohort study. Travel Med Infect Dis. 2019; 29:48-50. doi: 10.1016/j.tmaid.2019.03.004, PMID 30872071.
17. Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun. 2020;11(1):4968. doi: 10.1038/s41467-020-18786-x, PMID 33009413.
18. Bats ML, Rucheton B, Fleur T, Orieux A, Chemin C, Rubin S, et al. Covichem: A biochemical severity risk score of COVID-19 upon hospital admission. PLOS ONE. 2021; 16(5): e0250956. doi: 10.1371/journal. pone.0250956, PMID 33956870.
19. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-39. doi: 10.1007/s00281-017-0629-x. PMID 28466096, PMCID PMC7079893.
20. Bhavana P, Kumar VS, Divya N, Pratheek KP, and Rao GE. Assessment of the prescription pattern of oral hypoglycemic drugs in uncomplicated diabetes mellitus patients at a tertiary care hospital. Int J Pharm Sci & Res 2018; 9(8): 3487-92. doi: 10.13040/IJPSR.0975- 8232.9(8).3487-92.
21. Kumar VS, Kumar NDP, Ajay U, Jyothi PD, Rahaman SK A. Impact of Patient Counseling and Drug Utilization Pattern on Asthma Patients at Tertiary Care Hospital Int J Adv Pha Sci 2018;1[4]: 55-65.
22. Kumar VS, Manjula K, Ramyasri A, Nikitha D, Jyothi PD. Evaluation of Adherence to Therapy In Patients Of Hypertension At Tertiary Care Hospital. Br J Bio Med Res, July-Aug 2018; 2[4]:459-465; DOI: https://doi.org/ 10.24942/ bjbmr.2018.285.
23. Kumar VS, Ajay U, Bhargavi N, Nikitha D, Jyothi PD. Assessment and Drug Utilization Pattern on Antiplatelet Agents in cardiovascular patients - A Prospective Study in Tertiary Care Hospital. Int J Pham Pha Res, 2019; Vol 14[2]: 109-119.
24. Kumar VS, Rahaman SK, Deepika T, Manoj CH. Evaluation of Antibiotics and APACHE-II Score Correlation with Mortality in An Intensive Care Unit of Hepatic Impairment Patients at Tertiary Care Hospital Int. J. Pharm. Sci. Rev. Res., 59(1), 2019, 34-41.
25. Kumar VS, Bhavana P, Supriya CH, Rahaman SK A. Prevalence and Drug Utilization Pattern in Hepatic Impairment Patients at a Tertiary Care Hospital. Inter J Science Res, July 2017; 6[7]:1878- 1883 : https://www.ijsr.net/archive /v6i7/v6i7.
26. Kumar VS, Rahaman SK, Deepika T, Manoj CH. Prevalence and general medications utilization, cost minimization analysis of drugs in hepatic impairment patients at a tertiary care hospital research j. pharm. and tech. 2019; 12(10): 4873-4878. doi: 10.5958/0974-360x.2019.00844.8